Medroxyprogesterone acetate in non-metastatic gestational trophoblastic disease.
The effect of medroxyprogesterone acetate (MPA: Depo-Provera, Upjohn) as a contraceptive agent was assessed in 45 patients with non-metastatic gestational trophoblastic disease and compared with 13 patients using hormonal and 26 patients using non-hormonal methods of contraception. In the whole group of 84 patients 18 (21.4%) required chemotherapy. There was no statistically significant difference in the incidence of persistent trophoblastic disease between MPA (9/45) and the oral contraceptive group (2/13) and MPA and the non-hormonal contraceptive groups (7/26).
D000293:Adolescent; D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood*; D018997:Chorionic Gonadotropin, beta Subunit, Human; D003271:Contraceptive Agents, Female / Q000627:therapeutic use*; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D010446:Peptide Fragments / Q000097:blood*; D011247:Pregnancy; D011446:Prospective Studies; D012008:Recurrence; D014328:Trophoblastic Neoplasms / Q000097:blood* / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000097:blood* / Q000188:drug therapy
D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D010446:Peptide Fragments; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone